Market Tips

Home
Market Tips

We're NOT Financial Advisors! All the posts are for educational purposes ONLY! https://markettips.net/disclaimer/

24/06/2026

Tiny biotech. Big catalyst stack. 💥💥💥

A clinical-stage biotech story just hit the tape with multiple catalysts stacked at once:

✅ FDA orphan status already granted for measles
✅ Phase II Mpox treatment already shipped to the DR Congo
✅ Dosing expected in weeks
✅ Ebola pathway now advancing in the same region
✅ Oral gummy format built for real-world outbreak zones

For a name this small, that is a lot of attention sitting around one platform.

And when fresh biotech catalysts meet a chart that has shown it can move before… retail starts paying closer attention fast. 🔥

Details Here 👇
https://bit.ly/3QVVmGO

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

24/06/2026

The gummies are on a plane. ✈️

A broad-spectrum antiviral just shipped to the DR Congo for its Phase II trial — and the FDA already handed it *orphan status* for measles.

Measles. Mpox. The Ebola strain spreading there right now.

⛔ No approved cure for any of them — and this one's lining up against all three. 💉

Dosing begins in weeks.

Here's the full story 👇
https://bit.ly/4gB6i74

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

23/06/2026

Tomorrow at 8AM ET. ⏰

A tiny antiviral story is walking straight into the headlines nobody wants to see.

🦠 Measles surging
🌍 Mpox crossing borders
🚨 Ebola back under global-emergency attention

And here’s the twist…

One oral-gummy treatment candidate already has FDA orphan status for measles and has already shipped to the DRC for a Phase II Mpox trial. ✈️

Now Ebola just entered the path too.

Tiny name. Massive backdrop. Catalyst stack getting louder.

This could get attention fast. 👀

Full drop tomorrow at 8AM ET. 🔥
🔗 https://bit.ly/4g3Sd1R

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

22/06/2026

🛰️ A tiny defense name just keeps moving.

And the timing is hard to ignore. The Pentagon is proposing more than $70B for military drones and counter drone systems in its 2027 budget, while global counter drone awards reportedly topped $29B in just the first quarter of this year. 👀

That's the wave. This small name is paddling right into it. 🌊

New filings. New partners. New tech on public display. 🛡️

The kind of pace that's hard to fake and even harder to ignore. ⚡

Smart eyes are already pointed here.
Don't be the last to look. 👇
🔗 https://bit.ly/4g09w3Y

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

22/06/2026

👀 This one is starting to look less like a single headline and more like a full stack. 📚

RF sensing. 📡
AI coordination. 🤖
Autonomous platforms. 💻
3D perception. 🌐
Hardened data infrastructure. 🪖

And now a massive provisional filing tied to machine coordination across defense, security, and robotics.

Tiny name. Big ambition. Plenty of moving parts.

That is exactly why the radar is blinking.

Full story here 👇
🔗 https://bit.ly/3QZoYDb

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

21/06/2026

Something is setting up for tomorrow morning 📅☀️

Not just one headline.
Not just one shiny catalyst.

A small cap tech story has been quietly stacking pieces... and the pattern is starting to look a lot louder.

Full release hits tomorrow morning at 8AM ET.

Get ready to keep this one on your radar. 🔔
🔗 https://bit.ly/4uTwbTc

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

17/06/2026

📋 Here's what the data actually shows.

A first-in-class immunotherapy converting immune-resistant tumors into ones the body can fight — with clinical results running 2-3x above standard of care in some of the hardest-to-treat cancers on earth.

🛡️ The USPTO just issued a brand new patent protecting commercial manufacturing through 2044. That's not incremental. That's a commercial runway locked in by law.

Six a**lysts. Average target $5. One sitting at $10. But still in pennies. That gap is a fact, not an opinion.

📅 Data readouts could arrive before year end across three indications. The story is still early.

Full Breakdown 👉 https://bit.ly/4vTnN72

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

17/06/2026

📣 The full story is here, and it's stacking up fast.

🧬 First-in-class dsRNA immunotherapy targeting GI cancers — the fastest-growing cancer category in people under 50 worldwide.

📊 Clinical data that runs 2-3x above standard of care:

— OS: 27 months vs 11.2 months (colorectal)
— ORR: 33% vs 6-11% (colorectal)
— 2-year survival: ~22% vs 9.2% (pancreatic)

🛡️ Brand new U.S. patent issued June 16 protecting commercial manufacturing to 2044. Method-of-use filing pending — could extend to 2046. Total IP portfolio: 138 patents worldwide.

🧠 New board member from a $2 billion J&J deal. New COO from CG Oncology. Positive preclinical results in RAS-targeted combinations just announced.

📅 Multiple data readouts expected before year end — colorectal, a**l cancer, pancreatic.

📚 6 a**lysts. Average target: $5. One reiterated $10. Shares under $1.

That math is wide open. 👀
👉 https://bit.ly/4gkWVZa

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

16/06/2026

🔬 Something's building behind the scenes...

A first-in-class immunotherapy platform. Clinical data running 2-3x above standard of care in some of the hardest-to-treat cancers on the planet.

🛡️ A brand new U.S. patent just dropped — commercial manufacturing protected to 2044. Another filing pending that could push to 2046.
🧠 New board member. Fresh COO. Leadership that just closed a $2 billion deal at J&J.
📊 6 a**lysts covering it. Average target: $5. One just reiterated $10.

👀 Full report drops tomorrow at 9:30AM ET.

Don't miss it.
🔗 https://bit.ly/4uK8ywi

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

16/06/2026

🚨 Fresh news dropped — and it just made the story bigger.

A brand new veteran lung health program was just announced — and it brings some serious names to the table.

🏥 Philips — global health technology leader
🫁 NAVREF — the official VA research and education bridge to industry
🩻 4DMedical — advanced lung imaging technology
🎖️ Focus: U.S. veterans at increased lung cancer risk, including PACT Act exposures

A live expert panel webinar is set for July 21 featuring real-world case studies on how noninvasive CyPath® Lung testing fits into a broader veteran lung health strategy.

This dropped this morning — right before the market opened.

Today's feature just added another layer.

👇 Full breakdown here: https://bit.ly/4aU4aDN

Paid Promotion. We're NOT Financial Advisors! All posts are for educational purposes ONLY!

Address

Website

https://markettips.net/stock-news/, https://markettips.net/sign-up-sms/, https://t.me/+nIb1fH_SNOQ3MGU5

Alerts

Be the first to know and let us send you an email when Market Tips posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Advertising & Marketing Company?

Country:

City: